TC BioPharm Holdings PLC Overview
Industry: Biotechnology
Sector: Healthcare
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC BioPharm Holdings PLC is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review TC BioPharm Holdings PLC in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
TC BioPharm Holdings PLC Competitors
TC BioPharm Holdings PLC operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans